{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:03:34Z","timestamp":1785301414616,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Moderate-to-severe plaque psoriasis frequently coexists with metabolic comorbidities, yet the impact of interleukin-17 (IL-17) inhibitors on metabolic parameters remains inadequately characterized. This study evaluated the effects of IL-17 inhibitor therapy on glycemic control, lipid profiles, uric acid, and novel systemic inflammatory indices in psoriasis patients with metabolic comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This 48-week single-center retrospective study included 30 patients with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] \u226510 with \u22651 metabolic comorbidity) receiving IL-17 inhibitors (June 2023-December 2024). Fasting glucose, lipid profiles, uric acid, serum \u03b22-microglobulin, urinary albumin-to-creatinine ratio (UACR), homocysteine, systemic inflammation response index (SIRI), and systemic immune-inflammation index (SII) were assessed at baseline and weeks 12, 24, 36, and 48. The primary outcome was fasting glucose reduction \u226510% at week 48.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 48 weeks of treatment, PASI score decreased from 18.6 \u00b1 5.4 to 2.8 \u00b1 1.2 (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Fasting glucose decreased from 6.2 \u00b1 1.4 to 5.3 \u00b1 0.9 mmol\/L (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), triglycerides from 2.1 \u00b1 0.8 to 1.6 \u00b1 0.5 mmol\/L (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002), uric acid from 435 \u00b1 52 to 378 \u00b1 41 \u03bcmol\/L (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), and homocysteine from 14.2 \u00b1 3.5 to 10.8 \u00b1 2.6 \u03bcmol\/L (P &amp;lt; 0.001). SIRI decreased from 1.85 \u00b1 0.62 to 0.92 \u00b1 0.31 (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), and SII from 680 \u00b1 145 to 420 \u00b1 98 (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Multivariate analysis suggested that SIRI reduction may be an independent predictor of glycemic improvement [odds ratio (OR) = 2.68, 95% confidence interval (CI): 1.21\u20135.93,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.015] in this cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that IL-17 inhibitor therapy is associated with improvements in glycemic control, triglycerides, uric acid, homocysteine, and systemic inflammation in psoriasis patients with metabolic comorbidities. Preliminary evidence indicates that SIRI may serve as a practical clinical indicator for assessing metabolic improvement, although prospective validation is required. However, given the observational design, small sample size, lack of a control group, and absence of systematic data on lifestyle factors and direct measures of insulin resistance, these findings should be interpreted as hypothesis-generating and do not establish causality. Confirmation in larger prospective controlled studies is needed before any clinical recommendations can be made.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1891303","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:45:42Z","timestamp":1785300342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of IL-17 inhibitor therapy with glycemic, lipid profiles, and systemic inflammation in psoriasis patients with metabolic comorbidities: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xianzhe","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunYun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review.","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology.","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"594735","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside.","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"637829","DOI":"10.3389\/fimmu.2021.637829","article-title":"Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview.","volume":"12","author":"Schinocca","year":"2021","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/bjd.19262","article-title":"Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.","volume":"184","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.","volume":"5","author":"Papp","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials.","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/1346-8138.17755","article-title":"Efficacy and safety of IL-17 and IL-23 inhibitors in elderly patients with plaque psoriasis: a real-world study.","volume":"52","author":"Hac\u0131necipo\u011flu","year":"2025","journal-title":"J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing.","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1007\/s12325-025-03258-9","article-title":"Real-world evidence for ixekizumab in the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: systematic literature review 2022\u20132023.","volume":"42","author":"Puig","year":"2025","journal-title":"Adv Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"19933","DOI":"10.1038\/s41598-023-47292-5","article-title":"No associations between type 1 diabetes and atopic dermatitis, allergic rhinitis, or asthma in childhood: a nationwide Danish case-cohort study.","volume":"13","author":"Berg","year":"2023","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome.","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.","volume":"34","author":"Gerdes","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/bjd.12473","article-title":"Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis.","volume":"169","author":"Coto-Segura","year":"2013","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/1756-185X.14147","article-title":"Systematic review and meta-analysis on prevalence of metabolic syndrome in psoriatic arthritis, rheumatoid arthritis and psoriasis.","volume":"24","author":"Loganathan","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ejhf.113","article-title":"Psoriasis and risk of heart failure: a nationwide cohort study.","volume":"16","author":"Khalid","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1004591","DOI":"10.1371\/journal.pmed.1004591","article-title":"Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23: a population-based retrospective cohort study.","volume":"22","author":"Lin","year":"2025","journal-title":"PLoS Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1093\/eurheartj\/ehr285","article-title":"Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish nationwide cohort study.","volume":"33","author":"Ahlehoff","year":"2012","journal-title":"Eur Heart J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e60980","DOI":"10.7759\/cureus.60980","article-title":"The impact of interleukin-17 inhibitors on major adverse cardiovascular events in psoriasis or psoriatic arthritis patients naive to biologic agents: a systematic review and meta-analysis of randomized controlled trials.","volume":"16","author":"Ni","year":"2024","journal-title":"Cureus"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1891303\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:46:01Z","timestamp":1785300361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1891303\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1891303"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1891303","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1891303"}}